“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...

Qure (NASDAQ:QURE) shares added ~39% in the premarket on Thursday after the Dutch biotech announced that the FDA granted ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...

An innovative treatment for debilitating and often deadly cases of recurrent C diff infection has been given a Breakthrough Therapy Designation by the FDA. Developed by US biotech firm Rebiotix ...

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary ...

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández University of Elche (UMH, Spain) has developed a new method to deliver cell ...

Shares of uniQure N.V. (NASDAQ:QURE) surged 39% following the announcement that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to AMT-130, its gene therapy ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

Qure (QURE) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AMT-130 for the treatment ...